Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rienk Offringa

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicityGemma G Kenter, Marij J P Welters, A Rob P M Valentijn, et al.
International Journal of Cancer|April 12, 2008
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasiaMuriel van den Hende, Mariëtte I E van Poelgeest, Jeanette M van der Hulst, et al.
Cancer Research|February 5, 2003
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounterMarij J P Welters, Annemieke de Jong, Susan J F van den Eeden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell ClonesIsabel C Poschke, Jessica C Hassel, Aaron Rodriguez-Ehrenfried, et al.
Vaccine|November 9, 2004
Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour modelMarij J P Welters, Dmitri V Filippov, Susan J F van den Eeden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccineMarij J P Welters, Gemma G Kenter, Sytse J Piersma, et al.
Nature Medicine|March 22, 2006
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variantsThorbald van Hall, Elisabeth Z Wolpert, Peter van Veelen, et al.
The New England Journal of Medicine|November 6, 2009
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasiaGemma G Kenter, Marij J P Welters, A Rob P M Valentijn, et al.
Science Advances|April 10, 2026
Dissection of the T cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T cell repertoireHannes Kehm, Stefan Zens, Daniel Baumann, et al.
Nature|February 17, 2025
Characterization of single neurons reprogrammed by pancreatic cancerVera Thiel, Simon Renders, Jasper Panten, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicityGemma G Kenter, Marij J P Welters, A Rob P M Valentijn, et al.
International Journal of Cancer|April 12, 2008
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasiaMuriel van den Hende, Mariëtte I E van Poelgeest, Jeanette M van der Hulst, et al.
Cancer Research|February 5, 2003
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounterMarij J P Welters, Annemieke de Jong, Susan J F van den Eeden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell ClonesIsabel C Poschke, Jessica C Hassel, Aaron Rodriguez-Ehrenfried, et al.
Vaccine|November 9, 2004
Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour modelMarij J P Welters, Dmitri V Filippov, Susan J F van den Eeden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccineMarij J P Welters, Gemma G Kenter, Sytse J Piersma, et al.
Nature Medicine|March 22, 2006
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variantsThorbald van Hall, Elisabeth Z Wolpert, Peter van Veelen, et al.
The New England Journal of Medicine|November 6, 2009
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasiaGemma G Kenter, Marij J P Welters, A Rob P M Valentijn, et al.
Science Advances|April 10, 2026
Dissection of the T cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T cell repertoireHannes Kehm, Stefan Zens, Daniel Baumann, et al.
Nature|February 17, 2025
Characterization of single neurons reprogrammed by pancreatic cancerVera Thiel, Simon Renders, Jasper Panten, et al.
Pageof 12